Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia.

Steeghs EMP, Boer JM, Hoogkamer AQ, Boeree A, de Haas V, de Groot-Kruseman HA, Horstmann MA, Escherich G, Pieters R, den Boer ML.

Sci Rep. 2019 Mar 15;9(1):4634. doi: 10.1038/s41598-019-41078-4.

2.

NUTM1 is a recurrent fusion gene partner in B-cell precursor acute lymphoblastic leukemia associated with increased expression of genes on chromosome band 10p12.31-12.2.

Hormann FM, Hoogkamer AQ, Beverloo HB, Boeree A, Dingjan I, Wattel MM, Stam RW, Escherich G, Pieters R, den Boer ML, Boer JM.

Haematologica. 2019 Oct;104(10):e455-e459. doi: 10.3324/haematol.2018.206961. Epub 2019 Mar 14. No abstract available.

3.

Fibroblast growth factor receptor signaling in pediatric B-cell precursor acute lymphoblastic leukemia.

Jerchel IS, Hoogkamer AQ, Ariës IM, Boer JM, Besselink NJM, Koudijs MJ, Pieters R, den Boer ML.

Sci Rep. 2019 Feb 12;9(1):1875. doi: 10.1038/s41598-018-38169-z.

4.

High STAP1 expression in DUX4-rearranged cases is not suitable as therapeutic target in pediatric B-cell precursor acute lymphoblastic leukemia.

Steeghs EMP, Bakker M, Hoogkamer AQ, Boer JM, Hartman QJ, Stalpers F, Escherich G, de Haas V, de Groot-Kruseman HA, Pieters R, den Boer ML.

Sci Rep. 2018 Jan 12;8(1):693. doi: 10.1038/s41598-017-17704-4.

5.

High PDGFRA expression does not serve as an effective therapeutic target in ERG-deleted B-cell precursor acute lymphoblastic leukemia.

Jerchel IS, Chatzivasileiou D, Hoogkamer AQ, Boer JM, Beverloo HB, Pieters R, den Boer ML.

Haematologica. 2018 Feb;103(2):e73-e77. doi: 10.3324/haematol.2017.171702. Epub 2017 Nov 23. No abstract available.

6.

JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia.

Steeghs EMP, Jerchel IS, de Goffau-Nobel W, Hoogkamer AQ, Boer JM, Boeree A, van de Ven C, Koudijs MJ, Besselink NJM, de Groot-Kruseman HA, Zwaan CM, Horstmann MA, Pieters R, den Boer ML.

Oncotarget. 2017 Sep 16;8(52):89923-89938. doi: 10.18632/oncotarget.21027. eCollection 2017 Oct 27.

7.

RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia.

Jerchel IS, Hoogkamer AQ, Ariës IM, Steeghs EMP, Boer JM, Besselink NJM, Boeree A, van de Ven C, de Groot-Kruseman HA, de Haas V, Horstmann MA, Escherich G, Zwaan CM, Cuppen E, Koudijs MJ, Pieters R, den Boer ML.

Leukemia. 2018 Apr;32(4):931-940. doi: 10.1038/leu.2017.303. Epub 2017 Oct 3.

Supplemental Content

Loading ...
Support Center